|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| {{CMG}}
| | #REDIRECT [[Nifedipine#Patient Counseling Information]] |
| ==Instructions for administration==
| |
| <font size="4">[[Nifedipine instructions for administration#Overview|Overview]]</font>
| |
| <br>
| |
| <br>
| |
| <font size="4">[[Nifedipine instructions for administration#Angina patients|Angina patients]]</font>
| |
| <br>
| |
| <br>
| |
| <font size="4">[[Nifedipine instructions for administration#Discontinuation|Discontinuation]]</font>
| |
| <br<
| |
| <br>
| |
| <font size="4">[[Nifedipine instructions for administration#Co-administration with other antianginal drugs|Co-administration with other antianginal drugs]]</font>
| |
| <br>
| |
| ----
| |
| <br>
| |
| ===Overview===
| |
| Dosage must be adjusted according to each patient's needs. Therapy for either hypertension or angina should be initiated with 30 or 60 mg once daily. Nifedipine extended-release tablets should be swallowed whole and should not be bitten or divided. In general, titration should proceed over a 7–14 day period so that the physician can fully assess the response to each dose level and monitor blood pressure before proceeding to higher doses. Since steady-state plasma levels are achieved on the second day of dosing, if symptoms so warrant, titration may proceed more rapidly provided the patient is assessed frequently. Titration to doses above 120 mg are not recommended. ''[[Nifedipine instructions for administration#Instructions for administration|Return to top]]''
| |
| <br>
| |
| ===Angina patients===
| |
| Angina patients controlled on Nifedipine immediate-release capsules alone or in combination with other antianginal medications may be safely switched to Nifedipine extended-release tablets at the nearest equivalent total daily dose (e.g., 30 mg t.i.d. of Nifedipine immediate-release capsules may be changed to 90 mg once daily of Nifedipine extended-release tablets). Subsequent titration to higher or lower doses may be necessary and should be initiated as clinically warranted. Experience with doses greater than 90 mg in patients with angina is limited. Therefore, doses greater than 90 mg should be used with caution and only when clinically warranted. ''[[Nifedipine instructions for administration#Instructions for administration|Return to top]]''
| |
| <br>
| |
| ===Discontinuation===
| |
| No "rebound effect" has been observed upon discontinuation of Nifedipine extended-release tablets. However, if discontinuation of Nifedipine is necessary, sound clinical practice suggests that the dosage should be decreased gradually with close physician supervision. ''[[Nifedipine instructions for administration#Instructions for administration|Return to top]]''
| |
| <br>
| |
| ===Co-administration with other antianginal drugs===
| |
| Sublingual nitroglycerin may be taken as required for the control of acute manifestations of angina, particularly during Nifedipine titration. ''[[Nifedipine instructions for administration#Instructions for administration|Return to top]]''
| |
| <br>
| |
| <br>
| |
| ----
| |
| <br>
| |
| {{FDA}}
| |